FDA Label for Zourunan Pain Relief
View Indications, Usage & Precautions
Zourunan Pain Relief Product Label
The following document was submitted to the FDA by the labeler of this product Guchutang Biotechnology (longyan) Co., Ltd. The document includes published materials associated whith this product with the essential scientific information about this product as well as other prescribing information. Product labels may durg indications and usage, generic names, contraindications, active ingredients, strength dosage, routes of administration, appearance, warnings, inactive ingredients, etc.
Active Ingredient
Methyl salicylate 30%
Capsaicin 0.025%
Camphor 5%
Purpose
Topical analgesic
Use
Temporarily relieves muscle and stiffness due to:
■minor injuries
■overexertion
■falls reduces symptoms of bruising such as:
■pain■swelling■discoloration
Warnings
For external use only.
Do Not Use
you are allergic to cream or to any of this product's inactive ingredients.
When Using
Avoid contact with eyes, mucous membranes, wounds, damaged or irritated skin. Use only directed dryness or irritation may occurdo not tightly wrap or bandage the treated areado not apply heat or ice to treated area immediately before or after use.
Stop Use
Condition persists for more than 3 days or worsens osymptoms clear up and occur again within a few days.
Ask Doctor
Condition persists for more than 3 days or worsens osymptoms clear up and occur again within a few days.
Keep Out Of Reach Of Children
If swallowed, get medical help or contact a Poison Control Center right away.
Directions
Apply a thin layer of cream to the affected area as soon as possible after minor injury.Repeat 3 times a day or as needed. if heat or ice is applied, wait 5 minutes before applying cream.Children under 2 years of age: do not use, consult a physician or doctor.
Inactive Ingredients
PEG-100 stearate, Glycerol stearate, Cetyl stearol, water, Chlorphenylate, Phenoxyethanol, EDTA-2NA, Allantoin, Polydimethylsiloxane, Carbomer 940, Sodium hydroxide.
Principal Display Panel
* Please review the disclaimer below.
